Accelerate Diagnostics Inc. (AXDX) Sees Unusually-High Trading Volume
Accelerate Diagnostics Inc. (NASDAQ:AXDX) saw unusually-strong trading volume on Friday . Approximately 623,662 shares changed hands during trading, an increase of 71% from the previous session’s volume of 364,842 shares.The stock last traded at $19.65 and had previously closed at $19.07.
Several equities analysts have weighed in on AXDX shares. BTIG Research restated a “buy” rating and set a $26.00 target price on shares of Accelerate Diagnostics in a report on Wednesday, June 15th. Piper Jaffray Cos. reiterated a “buy” rating on shares of Accelerate Diagnostics in a report on Monday, April 11th. JPMorgan Chase & Co. began coverage on shares of Accelerate Diagnostics in a report on Thursday, March 24th. They set an “overweight” rating and a $17.00 price target for the company. Finally, Zacks Investment Research downgraded shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $22.67.
The company has a 50 day moving average price of $15.38 and a 200 day moving average price of $14.21. The stock’s market capitalization is $1.01 billion.
In related news, Director Jack W. Schuler acquired 101,272 shares of Accelerate Diagnostics stock in a transaction that occurred on Thursday, June 9th. The stock was acquired at an average price of $14.14 per share, with a total value of $1,431,986.08. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jack W. Schuler acquired 11,511 shares of Accelerate Diagnostics stock in a transaction that occurred on Monday, May 16th. The stock was bought at an average cost of $11.91 per share, with a total value of $137,096.01. The disclosure for this purchase can be found here.
A number of large investors recently bought and sold shares of the company. Neuberger Berman Group LLC increased its stake in Accelerate Diagnostics by 124.0% in the fourth quarter. Neuberger Berman Group LLC now owns 48,500 shares of the company’s stock valued at $1,042,000 after buying an additional 26,850 shares during the last quarter. Birchview Capital LP increased its stake in Accelerate Diagnostics by 4.3% in the fourth quarter. Birchview Capital LP now owns 2,155,795 shares of the company’s stock valued at $46,328,000 after buying an additional 88,235 shares during the last quarter. Finally, Tekla Capital Management LLC increased its stake in Accelerate Diagnostics by 83.0% in the fourth quarter. Tekla Capital Management LLC now owns 264,625 shares of the company’s stock valued at $5,687,000 after buying an additional 120,000 shares during the last quarter.
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.